Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
23 stopped studies mapped to Liposarcoma and descendants · 91% state a reason
Over the 23 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05496569 | TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma | Phase 2 | terminated | Aug 11, 2022 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT05580588 | Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or… | Phase 2 | terminated | Oct 14, 2022 | Shanghai Pharma Biotherapeutics USA Inc. | Although no safety issues with SPH4336 were identified, efficacy in liposarcoma patient was less… | Safety / toxicity |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for…(TOASTIT) | Early Phase 1 | terminated | Dec 30, 2019 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT04979442 | Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma(MANTRA) | Phase 3 | terminated | Jul 28, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03604783 | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | Phase 1 | terminated | Jul 27, 2018 | Sumitomo Pharma America, Inc. | Sponsor's decision to terminate further development of the program. | Sponsor / business decision |
| NCT03670069 | Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas | Phase 1 | terminated | Sep 13, 2018 | Fred Hutchinson Cancer Center | The study was terminated early with 27 out of 28 planned subjects enrolled. This decision was… | Enrollment / accrual |
| NCT05116683 | ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma(ATX-101) | Phase 2 | terminated | Nov 11, 2021 | Benjamin Izar | Study terminated by PI | Other (stated, no rule matched) |
| NCT05905341 | Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in… | Phase 1 | withdrawn | Jun 15, 2023 | Pfizer | This decision was based on business considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | Phase 1 | terminated | Jan 16, 2018 | University of Pennsylvania | Sponsor has terminated trial to pursue other targets. | Other (stated, no rule matched) |
| NCT03959033 | Patient Reported Outcome Measures (PROMs) With Trabectedin | — | terminated | May 22, 2019 | University of Leeds | Insufficient accrual | Enrollment / accrual |
| NCT03074318 | Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is… | Phase 1 / Phase 2 | terminated | Mar 8, 2017 | Fred Hutchinson Cancer Center | Terminated due to PI leaving institution | Other (stated, no rule matched) |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | Phase 2 | withdrawn | Nov 11, 2021 | Brown University | IND withdrawn | Other (stated, no rule matched) |
| NCT04906876 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With… | Phase 2 | withdrawn | May 28, 2021 | Brown University | IND withdrawn | Other (stated, no rule matched) |
| NCT01876043 | Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic,…(APLIPO) | Phase 2 | terminated | Jun 12, 2013 | Institut Bergonié | not stated | Not stated |
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Phase 1 | withdrawn | Mar 19, 2019 | Matthew Ingham | Study will not proceed, no participants enrolled. | Enrollment / accrual |
| NCT02609984 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab… | Phase 2 | terminated | Nov 20, 2015 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | This study did not meet the efficacy objective | Efficacy / futility |
| NCT03397186 | Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma | Phase 2 | withdrawn | Jan 11, 2018 | Fred Hutchinson Cancer Center | Administrative | Other (stated, no rule matched) |
| NCT01957709 | Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma | Early Phase 1 | terminated | Oct 8, 2013 | Fred Hutchinson Cancer Center | Enough samples were collected for data analysis. | Other (stated, no rule matched) |
| NCT03773510 | Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin(TRADITIONS) | Phase 3 | withdrawn | Dec 12, 2018 | Italian Sarcoma Group | Not approved by the coordinating Ethical Committee | Other (stated, no rule matched) |
| NCT02059850 | NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced… | Phase 1 | withdrawn | Feb 11, 2014 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT00969917 | Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced… | Phase 2 | withdrawn | Sep 2, 2009 | Infinity Pharmaceuticals, Inc. | Company decision not to start the study | Sponsor / business decision |
| NCT00233948 | Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable… | Phase 1 / Phase 2 | terminated | Oct 6, 2005 | City of Hope Medical Center | Drug availability issues | Drug supply |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Nov 21, 2025source: clinicaltrials